Abstract
It has been shown that some chalcones are able to inhibit tubulin polymerization, giving cytotoxicity and destruction of tumoral vasculature. A library of 180 novel chalcone analogs has been synthesized via click chemistry and screened for their cytotoxicity and tubulin assembly inhibition. 10 out 180 click chalcones displayed low micromolar cytotoxicity but only compound Nf depicted antitubulin activity. While Nf displayed only micromolar potency this result shows click-chalcones may be anti-tubulin agents and validate this strategy to search for novel active chemical entities.
Keywords: Antitubulinic agent, Cancer, Chalcone analogs, Click chemistry, Cytotoxicity, Tubulin
Medicinal Chemistry
Title:Parallel Synthesis of “Click” Chalcones as Antitubulin Agents
Volume: 9 Issue: 4
Author(s): Maleeruk Utsintong, Alberto Massarotti, Antonio Caldarelli and Sewan Theeramunkong
Affiliation:
Keywords: Antitubulinic agent, Cancer, Chalcone analogs, Click chemistry, Cytotoxicity, Tubulin
Abstract: It has been shown that some chalcones are able to inhibit tubulin polymerization, giving cytotoxicity and destruction of tumoral vasculature. A library of 180 novel chalcone analogs has been synthesized via click chemistry and screened for their cytotoxicity and tubulin assembly inhibition. 10 out 180 click chalcones displayed low micromolar cytotoxicity but only compound Nf depicted antitubulin activity. While Nf displayed only micromolar potency this result shows click-chalcones may be anti-tubulin agents and validate this strategy to search for novel active chemical entities.
Export Options
About this article
Cite this article as:
Utsintong Maleeruk, Massarotti Alberto, Caldarelli Antonio and Theeramunkong Sewan, Parallel Synthesis of “Click” Chalcones as Antitubulin Agents, Medicinal Chemistry 2013; 9 (4) . https://dx.doi.org/10.2174/1573406411309040004
| DOI https://dx.doi.org/10.2174/1573406411309040004 |
Print ISSN 1573-4064 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functionalized Mesoporous Silica Nanoparticles: A Possible Strategy to Target Cancer Cells Reducing Peripheral Nervous System Uptake
Current Medicinal Chemistry Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Neuroprotective Effects of Ellagitannins: A Brief Review
Current Drug Targets The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Current Non-viral Gene Therapy Strategies for the Treatment of Glioblastoma
Current Medicinal Chemistry Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Cyclization in Opioid Peptides
Current Drug Targets Formulation and Characterization of Rutin Loaded Chitosan-alginate Nanoparticles: Antidiabetic and Cytotoxicity Studies
Current Drug Delivery Carbohydrate Mimotopes in the Rational Design of Cancer Vaccines
Current Topics in Medicinal Chemistry Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis
Current Cancer Drug Targets Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Getting Rid of Intracellular Aβ - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons
Current Pharmaceutical Design Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Clinical Characteristics and Risk Factors for Bloodstream Infections in Children with Cancer: A Report from a Pediatric Hematology Oncology Unit
Cardiovascular & Hematological Agents in Medicinal Chemistry New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Melatonin and Synthetic Melatonergic Agonists: Actions and Metabolism in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry





